"Biologick\u00E1 l\u00E9\u010Dba karcinomu ledviny" . . "Zemanov\u00E1, Milada" . . "Biologick\u00E1 l\u00E9\u010Dba karcinomu ledviny"@cs . "CZ - \u010Cesk\u00E1 republika" . . "Renal cell carcinoma; sorafenib; sunitinib; bevacizumab; pazopanib; everolimus; temsirolimus"@en . "Biologick\u00E1 l\u00E9\u010Dba karcinomu ledviny" . "RIV/00064165:_____/12:13012" . . "3" . . . "RIV/00064165:_____/12:13012!RIV13-MZ0-00064165" . "Biologick\u00E1 l\u00E9\u010Dba karcinomu ledviny"@cs . "Urologie pro praxi" . "1"^^ . "125090" . "[9821E0EE38EE]" . . . . . . . . . "1"^^ . "http://www.urologiepropraxi.cz/pdfs/uro/2012/03/03.pdf" . "The basis of treatment for localized renal cell carcinoma is surgery. The treatment of advanced and metastatic stages is based on systemic therapy in combination with cytoreductive local approaches. Cytokines, used in the past, may currently be beneficial for patients in a good prognostic group, but molecularly targeted biological treatment, mainly directed at key points of the defective VHL/HIF pathway, showed significantly better efficacy in patients of all prognostic groups with prolonged survival compared to interferon alpha. Currently tyrosinekinase receptor inhibitors for angiogenic growth factors, sorafenib, sunitinib and pazopanib, monoclonal antibody neutralizing vascular endothelial growth factor bevacizumab and mTOR kinase inhibitors temsirolimus and everolimus are registered for the first or second-line treatment of advanced and/or metastatic disease. The testing of targeted medicines adjuvant administration contribution takes place at the level of phase III studies."@en . . . "Biological treatment of renal cell cancer"@en . "Z\u00E1kladem l\u00E9\u010Dby lokalizovan\u00E9ho karcinomu ledviny je operace. L\u00E9\u010Dba pokro\u010Dil\u00FDch a metastazuj\u00EDc\u00EDch stadi\u00ED spo\u010D\u00EDv\u00E1 v syst\u00E9mov\u00E9 terapii v kombinaci s cytoreduk\u010Dn\u00EDmi lok\u00E1ln\u00EDmi postupy. V minulosti pod\u00E1van\u00E9 cytokiny mohou b\u00FDt dnes prosp\u011B\u0161n\u00E9 u nemocn\u00FDch v dobr\u00E9 prognostick\u00E9 skupin\u011B, ale molekul\u00E1rn\u011B c\u00EDlen\u00E1 biologick\u00E1 l\u00E9\u010Dba, zam\u011B\u0159en\u00E1 hlavn\u011B na kl\u00ED\u010Dov\u00E1 m\u00EDsta defektn\u00ED trasy VHL/HIF, prok\u00E1zala v\u00FDznamn\u011B lep\u0161\u00ED \u00FA\u010Dinnost u pacient\u016F v\u0161ech prognostick\u00FDch skupin s del\u0161\u00EDm p\u0159e\u017Eit\u00EDm ve srovn\u00E1n\u00ED s interferonem alfa. V sou\u010Dasn\u00E9 dob\u011B jsou registrov\u00E1ny k terapii prvn\u00ED nebo druh\u00E9 linie pokro\u010Dil\u00E9ho a/nebo metastazuj\u00EDc\u00EDho onemocn\u011Bn\u00ED tyrozinkin\u00E1zov\u00E9 inhibitory receptor\u016F pro angiogenn\u00ED r\u016Fstov\u00E9 faktory sorafenib, sunitinib a pazopanib, monoklon\u00E1ln\u00ED protil\u00E1tka neutralizuj\u00EDc\u00ED vaskul\u00E1rn\u00ED endoteli\u00E1ln\u00ED r\u016Fstov\u00FD faktor bevacizumab a inhibitory mTOR kin\u00E1zy temsirolimus a everolimus. Testov\u00E1n\u00ED p\u0159\u00EDnosu adjuvantn\u00EDho pod\u00E1v\u00E1n\u00ED c\u00EDlen\u00FDch prost\u0159edk\u016F prob\u00EDh\u00E1 na \u00FArovni studi\u00ED f\u00E1ze III." . "V" . "Biological treatment of renal cell cancer"@en . . "13" . "6"^^ . . "Z\u00E1kladem l\u00E9\u010Dby lokalizovan\u00E9ho karcinomu ledviny je operace. L\u00E9\u010Dba pokro\u010Dil\u00FDch a metastazuj\u00EDc\u00EDch stadi\u00ED spo\u010D\u00EDv\u00E1 v syst\u00E9mov\u00E9 terapii v kombinaci s cytoreduk\u010Dn\u00EDmi lok\u00E1ln\u00EDmi postupy. V minulosti pod\u00E1van\u00E9 cytokiny mohou b\u00FDt dnes prosp\u011B\u0161n\u00E9 u nemocn\u00FDch v dobr\u00E9 prognostick\u00E9 skupin\u011B, ale molekul\u00E1rn\u011B c\u00EDlen\u00E1 biologick\u00E1 l\u00E9\u010Dba, zam\u011B\u0159en\u00E1 hlavn\u011B na kl\u00ED\u010Dov\u00E1 m\u00EDsta defektn\u00ED trasy VHL/HIF, prok\u00E1zala v\u00FDznamn\u011B lep\u0161\u00ED \u00FA\u010Dinnost u pacient\u016F v\u0161ech prognostick\u00FDch skupin s del\u0161\u00EDm p\u0159e\u017Eit\u00EDm ve srovn\u00E1n\u00ED s interferonem alfa. V sou\u010Dasn\u00E9 dob\u011B jsou registrov\u00E1ny k terapii prvn\u00ED nebo druh\u00E9 linie pokro\u010Dil\u00E9ho a/nebo metastazuj\u00EDc\u00EDho onemocn\u011Bn\u00ED tyrozinkin\u00E1zov\u00E9 inhibitory receptor\u016F pro angiogenn\u00ED r\u016Fstov\u00E9 faktory sorafenib, sunitinib a pazopanib, monoklon\u00E1ln\u00ED protil\u00E1tka neutralizuj\u00EDc\u00ED vaskul\u00E1rn\u00ED endoteli\u00E1ln\u00ED r\u016Fstov\u00FD faktor bevacizumab a inhibitory mTOR kin\u00E1zy temsirolimus a everolimus. Testov\u00E1n\u00ED p\u0159\u00EDnosu adjuvantn\u00EDho pod\u00E1v\u00E1n\u00ED c\u00EDlen\u00FDch prost\u0159edk\u016F prob\u00EDh\u00E1 na \u00FArovni studi\u00ED f\u00E1ze III."@cs . . "1213-1768" .